Association Between Smell Loss, Disease Burden, and Dupilumab Efficacy in Chronic Rhinosinusitis with Nasal Polyps
Significant smell impairment in severe CRSwNP is associated with significant disease (NC, RS-VAS, LMK), health-related quality of life impairment (SNOT-22), asthma, and non-steroidal anti-inflammatory drug-exacerbated respiratory disease. Dupilumab significantly improved NPS, NC, LMK-CT, RS-VAS, and SNOT-22 in subjects with moderate and severe baseline smell loss.
Authors
- Harry Sacks (ORCID: https://orcid.org/0009-0000-9136-4253)
- Juby A. Jacob‐Nara (ORCID: https://orcid.org/0000-0002-5372-8762)
- Andrew P. Lane (ORCID: https://orcid.org/0000-0001-6369-5469)
- Kinga Borsos
- Scott Nash (ORCID: https://orcid.org/0000-0001-9208-5280)
- Paul Rowe (ORCID: https://orcid.org/0000-0002-7864-9286)
- Yamo Deniz
- Mark Corbett (ORCID: https://orcid.org/0000-0001-9298-3072)
- Zara M. Patel (ORCID: https://orcid.org/0000-0003-2072-982X)
- Zachary M. Soler (ORCID: https://orcid.org/0000-0002-4304-595X)
- José L. Mattos (ORCID: https://orcid.org/0000-0001-8766-1626)
- Zhixiao Wang (ORCID: https://orcid.org/0000-0003-1928-3103)
- Changming Xia (ORCID: https://orcid.org/0000-0002-5703-5074)
- Joaquim Mullol
Institutions
- Johns Hopkins University (US)
- Medical University of South Carolina (US)
- Regeneron (United States) (US)
- University of Virginia Health System (US)
- Johns Hopkins Medicine (US)
- Sanofi (United States) (US)
- Hospital Clínic de Barcelona (ES)
- Universitat de Barcelona (ES)
- Stanford University (US)
Publication Details
- Journal
- American Journal of Rhinology and Allergy
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1177/19458924241274501
- Citations
- 4
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 2.32
Funders
- Sanofi
- Regeneron Pharmaceuticals